Switching from clopidogrel to prasugrel in patients having coronary stent implantation
- 531 Downloads
There are very few clinical data concerning the safety of switching from clopidogrel to prasugrel in patients undergoing coronary stenting. However, in the daily activity, clinicians face the decision of switching patients at high-risk of thrombotic events from clopidogrel to prasugrel. Thus, we sought to evaluate clinical events in patients undergoing coronary stent implantation and prasugrel therapy with (SWITCH group) or without (NAÏVE group) prior clopidogrel therapy. A total of 454 patients with stable or unstable coronary artery disease, aged 70 ± 10 years, underwent non-emergent stent implantation and received prasugrel therapy. Of these, 315 (69 %) patients received clopidogrel before switching to prasugrel therapy. In 239 patients with high residual platelet reactivity (HRPR) on clopidogrel, prasugrel decreased platelet aggregation from 72 ± 11 to 43 ± 16 % (p < 0.001). There was no difference in in-hospital major or minor TIMI bleeding (2.8 vs. 4.3 %; p = 0.411) between the SWITCH and NAÏVE groups as well as in mortality, acute stent thrombosis, reinfarction and stroke rates. At multivariable analysis, independent predictors of bleeding were female gender (OR 5.56 [1.41–19.88] p = 0.014) and chronic renal failure (OR 6.27 [1.59–21.65] p = 0.009), but switching therapy did not. This result was confirmed after switching propensity score adjustment (c-statistic 0.81; Hosmer–Lemeshow test p = 860). Switching from clopidogrel to prasugrel in patients undergoing non-emergent coronary stent implantation seems to be tolerated with no overt signs of increased bleeding.
KeywordsPrasugrel Stent Switching Bleeding Acute coronary syndromes
This study was supported by the A.R. CARD Foundation, Florence, Italy.
- 1.Wiviott SD, Trenk D, Frelinger AL, PRINCIPLE-TIMI 44 Investigators et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116:2923–2932PubMedCrossRefGoogle Scholar
- 2.Wiviott SD, Antman EM, Winters KJ, JUMBO-TIMI 26 Investigators et al (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 111:3366–3373PubMedCrossRefGoogle Scholar
- 5.Levine GN, Bates ER, Blankenship JC, ACCF, AHA, SCAI Practice Guidelines et al (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary (2011). A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124:2574–2609PubMedCrossRefGoogle Scholar
- 6.Wiviott SD, Braunwald E, Angiolillo DJ, TRITON-TIMI 38 investigators et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118:1626–1636PubMedCrossRefGoogle Scholar
- 8.Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38 investigators et al (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371:1353–1363PubMedCrossRefGoogle Scholar
- 12.Erlinge D, Gurbel PA, James S et al (2013) Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients: the generations trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 1097:2161–2162Google Scholar
- 19.Brandt JT, Payne CD, Wiviott SD et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(66):9–16Google Scholar
- 21.Angiolillo DJ, Saucedo JF, Deraad R, SWAP Investigators et al (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56:1017–1023PubMedCrossRefGoogle Scholar